Aktis Oncology, Inc.
AKTS
Rank in Stocks
#9263
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to... Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Share Price
$16.37
Last synced: 2026-11-09
Market Cap
$879.83M
Change (1 day)
3.48%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aktis Oncology, Inc. (AKTS)
Category
Healthcare
Operating Margin for Aktis Oncology, Inc. (AKTS)
Operating Margin as of November 2026 TTM: -866.63%
According to Aktis Oncology, Inc.'s latest financial reports, its current operating margin (TTM) is -866.63%. At the end of 2025 the company had an operating margin of -1,149.52%.
Operating Margin history for Aktis Oncology, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -866.63% | -24.61% |
| 2025 | -1,149.52% | -67.16% |
| 2024 | -3,500.34% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -625.48% | -65.05% |
| 2020 | -1,789.83% | -6.14% |
| 2019 | -1,906.93% | 3.39% |
| 2018 | -1,844.39% | -96.86% |
| 2017 | -58,704.12% | 3,087.01% |
| 2016 | -1,841.98% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.83% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Aktis Oncology, Inc.'s operating margin
What is Aktis Oncology, Inc.'s operating margin?
Aktis Oncology, Inc.'s operating margin is -866.63%, as of Nov 2026.
What was Aktis Oncology, Inc.'s operating margin in 2025?
In 2025, Aktis Oncology, Inc.'s operating margin was -1,149.52%, compared with -3,500.34% in 2024.
How has Aktis Oncology, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Aktis Oncology, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-3,500.34%).
How does Aktis Oncology, Inc.'s operating margin compare with similar companies?
Aktis Oncology, Inc.'s operating margin (-866.63%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.